A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Molecular Medicine

• Publication date

  2006-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJMM.18.4.751PMID 16964432PMCID PMC2203218
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22‐HSVTk‐GFP triple fusion construct

  2005cited by this paper
• Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

  2005cited by this paper
• Fluorescently Labeled Adenovirus with pIX-EGFP for Vector Detection

  2004cited by this paper
• Adenoviral vectors for gene transfer and therapy

  2004cited by this paper
• Fluorescently labeled adenovirus with pIX-EGFP for vector detection.

  2004cited by this paper
• Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector

  2004cited by this paper
• Modified adenoviruses for cancer gene therapy

  2004cited by this paper
• Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo.

  2004cited by this paper
• 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene

  2004cited by this paper
• Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential

  2003cited by this paper
• Disruption of gap junctions in toxicity and carcinogenicity.

  2003cited by this paper
• Gene therapy with viral vectors.

  2003cited by this paper
• Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.

  2003cited by this paper
• A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy

  2003cited by this paper
• Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.

  2003cited by this paper
• A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene.

  2002cited by this paper
• Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.

  2002cited by this paper
• Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

  2002cited by this paper
• Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

  2002cited by this paper
• Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

  2002cited by this paper
• Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.

  2002cited by this paper
• Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy

  2001cited by this paper
• Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

  2001cited by this paper
• Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

  2001cited by this paper
• Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing.

  2001cited by this paper
• A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.

  2001cited by this paper
• The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.

  2000cited by this paper
• In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

  2000cited by this paper
• Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk.

  2000cited by this paper
• A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

  2000influential reference
• A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

  2000cited by this paper
• Double Suicide Gene Therapy Augments the Antitumor Activity of a Replication-Competent Lytic Adenovirus through Enhanced Cytotoxicity and Radiosensitization

  2000cited by this paper
• Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

  1999cited by this paper
• Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant

  1999cited by this paper
• Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.

  1999cited by this paper
• A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy

  1998cited by this paper
• Herpes simplex virus thymidine kinase-green fluorescent protein fusion gene: new tool for gene transfer studies and gene therapy.

  1998cited by this paper
• Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir.

  1998cited by this paper
• Visualizing Gene Expression in Living Mammals Using a Bioluminescent Reporter

  1997cited by this paper
• Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins.

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• New developments in the virus therapy of cancer: a historical review.

  1993cited by this paper
• In Vitro Evidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSV tk Retroviral Gene Therapy

  1993cited by this paper
• Experimental therapy of human glioma by means of a genetically engineered virus mutant

  1991cited by this paper

• Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity.

  2021cites this paper
• Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer

  2020cites this paper
• In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders

  2014cites this paper
• Combining virotherapy and angiotherapy for the treatment of breast cancer

  2013cites this paper
• Hypolipidemic effect of SR‑BI gene delivery by combining cationic liposomal microbubbles and ultrasound in hypercholesterolemic rats.

  2013cites this paper
• Conditionally Replicating Adenovirus Expressing TIMP2 Increases Survival in a Mouse Model of Disseminated Ovarian Cancer

  2011cites this paper
• The Role of Natural Killer Cells in the Context of Oncolytic Herpes Simplex Virotherapy for Glioblastoma

  2011cites this paper
• A TIMP2-armed conditionally-replicating adenovirus for the treatment of ovarian cancer

  2010cites this paper
• Approaches for improving the safety and efficacy of adenoviral gene therapy

  2010cites this paper
• Intelligent Design: Combination Therapy With Oncolytic Viruses.

  2010cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Armed replicating adenoviruses for cancer virotherapy

  2009cites this paper
• Cancer gene therapy with oncolytic adenoviruses.

  2009cites this paper
• Assessment of Genetic Shielding for Adenovirus Vectors

  2009cites this paper
• Genetically Engineered Oncolytic Adenoviruses for the Treatment of Kidney and Breast Cancer

  2009cites this paper
• Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma.

  2009cites this paper
• Novel Infectivity-Enhanced Oncolytic Adenovirus with a Capsid-Incorporated Dual-Imaging Moiety for Monitoring Virotherapy in Ovarian Cancer

  2009cites this paper
• Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.

  2009cites this paper
• Oncolytic adenoviruses for treatment of ovarian cancer

  2009cites this paper
• Gene and Virotherapy Against Osteosarcoma

  2009cites this paper
• Viruses, gene therapy and stem cells for the treatment of human glioma

  2009cites this paper
• Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.

  2008cites this paper
• Replication competent Semliki Forest virus prolongs survival in experimental lung cancer

  2008cites this paper
• Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.

  2008cites this paper
• Adenoviral gene therapy for non-small cell lung cancer

  2008influential citation
• Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.

  2007cites this paper
• Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo

  2007cites this paper
• GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the TAT8-TK as a late gene in a pancreatic tumour model

  2007cites this paper
• Type I interferon response against viral and non‐viral gene transfer in human tumor and primary cell lines

  2007cites this paper
• Hurdles and Improvements in Therapeutic Gene Transfer for Cancer

  2007cites this paper
• Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus

  2007cites this paper
• Development of Gene and Virotherapy Against Non-Small Cell Lung Cancer

  2007cites this paper